Trina J. Stewart
Trina J. Stewart received her Ph.D. degree in medicine from The University of Queensland, Brisbane, QLD, Australia, in 2002 at the Centre for Immunology and Cancer Research (now Diamantina Institute), where she studied the characteristics of adoptively transferred cell populations that facilitated the regression of established 16E7-expressing tumors, particularly a comparison between bulk and CTL line transfers. She then went on to undertake postdoctoral training at the National Cancer Institute (NCI), National Institutes of Health (NIH), in Bethesda, Md, USA. There, she investigated the consequences and changes to the immune system of progressive tumor growth using a spontaneous, long-term model of mammary carcinoma. A large part of these studies was an investigation into the role of IRF-8 in myeloid-derived suppressor cell biology. After 5.5 years in the USA, Dr Stewart moved back to Australia to take up a position at the Peter MacCallum Cancer Centre in Melbourne, in the Cancer Immunology Program. She has established a program investigating the role of the chemokine CCL2 in tumor progression and immunosuppression and the use of anti-CCL2 monoclonal antibody as an immunotherapeutic for the treatment of breast cancer. Trina has now moved to Griffith University where her continuing interests lie in the fields of cancer stem cell immunobiology and cancer immunotherapy, particularly the role of immunosuppressive mechanisms and how these barriers may be mitigated to enhance other therapies and the use of immunotherapeutic strategies to target cancer stem cells.
Biography Updated on 9 December 2012